Research programme: gene editing based therapeutics - Casebia Therapeutics

Drug Profile

Research programme: gene editing based therapeutics - Casebia Therapeutics

Alternative Names: CRISPR/Cas9 gene editing therapies - Bayer-CRISPR Therapeutics

Latest Information Update: 11 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Casebia Therapeutics
  • Class Cardiovascular therapies; Eye disorder therapies; Gene therapies
  • Mechanism of Action Gene modulators; Gene transference; Immunogenetic modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Blindness; Congenital heart defects; Haemophilia; Immunodeficiency disorders

Most Recent Events

  • 22 Jun 2018 ERS genomics, the University of California and University of Vienna has patent protection for CRISPR/Cas9 technology for gene editing in the US, the EU and Japan
  • 19 Jun 2018 ERS Genomis and University of California have patent protection for CRISPR/Cas9 technology for gene editing in Japan, Australia, New Zealand, Mexico before June 2018
  • 14 Nov 2017 CureVac and Casebia Therapeutics enter into a collaboration agreement for the development of gene-editing programmes
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top